Author

Medically Speaking Team

Uncategorized

Medical college doctor booked for assaulting nurses

by Medically Speaking Team August 5, 2021

written by Medically Speaking Team

A case was registered against a doctor attached to Government Medical College Hospital (MCH), Kalamassery, on the complaint of two nurses alleging physical assault and a bid to defame them. As per the petition, the doctor attached to the Department of Medicine beat up the nurses when they didn’t give an official file he sought.

According to the police, the incident occurred two months ago and the MCH authorities had constituted a two-member commission to conduct a probe. The panel later submitted that the allegations levelled were baseless, following which the nurses lodged a police complaint.

August 5, 2021 0 comment

Uncategorized

Combination of Sputnik V component with AstraZeneca, Sinopharm and Moderna shows high safety: RDIF study

by Medically Speaking Team August 5, 2021

written by Medically Speaking Team

In a finding that could provide a boost to the global fight against COVID-19, Russian researchers have discovered that a combination of variants of Sputnik V with vaccines of AstraZeneca, Sinopharm, and Moderna could provide immunity against COVID-19. A study by the Russian Direct Investment Fund (RDIF) has said that the approach could provide a longer and more durable immunity against the deadly virus.

“A study was conducted in Argentina, in which, the heterogeneous boosting approach (‘vaccine cocktail’ using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V, the world’s first registered vaccine against coronavirus. With this approach proving successful in creating a longer and more durable immunity against the coronavirus,” RDIF said in a statement.

According to news agency ANI, 121 volunteers were analysed in the regimens – Sputnik Light/AstraZeneca, Sputnik Light/Moderna, Sputnik Light/Sinopharm, Sputnik Light/Sputnik Light compared to control group Sputnik V 1 Comp./Sputnik V 2 Comp.

Sputnik V is effective against the Delta variant of COVID-19: Study

“RDIF is the first country to offer vaccine cooperation to other producers to conduct joint mix and match studies. This approach is the most promising one to fight the pandemic and new strains of coronavirus emerging around the world,” Kirill Dmitriev, CEO of RDIF said.

The outcome of the study may be important given that it could strengthen the ongoing global fight against the deadly virus. In India, Sputnik is being produced in partnership with the Serum Institute of India, the largest vaccine producer in the world. A recent study has shown that it is one of the most effective vaccines against COVID-19, including its Delta variant.

August 5, 2021 0 comment

Uncategorized

Sputnik V, AstraZeneca booster dose trial result expected this week: Report

by Medically Speaking Team August 5, 2021

written by Medically Speaking Team

The Russian Direct Investment Fund (RDIF) has recently issued a statement regarding the trials conducted about the booster dose of Sputnik V and Astrazeneca trials which has not shown any adverse effects. According to news agency ANI more trials are still underway and it is expected to announce more results this week.

The government has also given its view on mixing of two vaccines for Covid-19. Minister of state for health Bharati Pravin Pawar in a written reply in the Rajya Sabha said,”Covid-19 vaccines have been developed recently. Therefore, scientific evidence about mix and match studies of different vaccines is still evolving.”

Meanwhile, Dr Reddy’s Laboratories issued a statement on 2 August regarding the availability of ‘Made in India’ Sputnik V COVID-19 doses from September /October, the Sputnik V team confirmed it was scaling up its vaccine production capacity.

Sputnik V team said in a statement,”Sputnik V team confirms that owing to a major scale-up in vaccine production capacity temporary second component delivery delays that occurred due to this production scale-up will be fully resolved in August.”

“Sputnik V has built production partnership with producers in 14 countries and will additionally double its capacity in September thanks to our partnership with top producers including Serum Institute of India, the world’s largest vaccine producer,” reads the statement.

“Sputnik V will also continue to play a leading role in vaccine combinations (mix and match approach). Sputnik V, which pioneered the heterogeneous boosting (vaccine cocktail) approach by using two different adenoviral vectors (Ad5 and Ad26) for two different shots, was first to offer a joint mix and match trial to another producer when it made an offer to AstraZeneca on November 23, 2020. Joint Sputnik V and AstraZeneca trials have been ongoing in the United Arab Emirates, Azerbaijan, and Argentina since February 2021. The early positive results were announced on July 30. More positive results on immunogenicity are expected this week,” it added.

August 5, 2021 0 comment

Uncategorized

WHO calls for halt on booster shots for Delta variant

by Medically Speaking Team August 5, 2021

written by Medically Speaking Team

The World Health Organization is asking for a COVID-19 vaccine booster embargo until at least the end of September, according to Tedros Adhanom Ghebreyesus, the organization’s director-general.
According to WHO Director-General Tedros, the decision was made to ensure that at least 10% of the population of each nation got vaccinated.

As the disparity in immunisation rates in affluent and poor nations grows, the UN agency has issued its strongest demand yet to suspend COVID-19 vaccine boosters.

“I understand the concern of all governments to protect their people from the Delta variant. But we cannot accept countries that have already used most of the global supply of vaccines using even more of it,” Tedros added.

High-income countries administered around 50 doses for every 100 people in May, and that number had since doubled, according to WHO. Low-income countries have only been able to administer 1.5 doses for every 100 people, due to lack of supply.

“We need an urgent reversal, from the majority of vaccines going to high-income countries, to the majority going to low-income countries,” said Tedros.

Some countries have begun to use or started weighing on the need for booster doses.

August 5, 2021 0 comment

Uncategorized

People with both doses of Covishield have higher immunity against Delta variant ICMR study suggests

by Medically Speaking Team August 4, 2021

written by Medically Speaking Team

New Delhi: A study published by ICMR and National Institute of Virology, Pune shows that people with both doses of Covishield vaccine have higher immunity against the Delta variant of the coronavirus.

It also said that COVID-19 recovered individuals who were administered Covishield had higher neutralizing responses against the Delta variant.

“The study demonstrated that the breakthrough cases and the COVID-19 recovered individuals with one or two doses of Covishield vaccine had relatively higher neutralizing responses against the Delta variant in comparison to the participants who were administered either one or two doses of Covishield,” it said.

A comparative assessment of Covishield vaccinated individuals were conducted and sera under this study were grouped into five categories: People who took one dose, those who were administered two doses, COVID-19 recovered people who got one dose, COVID-19 recovered individuals who received two doses and breakthrough COVID-19 cases.

An increase in NAb titers was observed for both B.1 and Delta variants in the sera of the participants who had completed two vaccine doses relative to one dose.

Neutralizing antibody titers against B.1 and Delta variants were highest among breakthrough participants which may be due to spike-specific T-cell responses.

A titer is a test that measures the presence and amount of antibodies in the blood.

The study found that significantly lower NAb titers were observed for the Delta relative to B.1 variant. However, NAbs in breakthrough participants and the COVID-19 recovered individuals with one or two-dose vaccination had relatively higher protection against Delta in comparison to the vaccines with one or two-dose vaccination.

Long-term follow-up of participants could help to understand the impact of natural infection and vaccination on long-term protection from SARS-CoV-2 offered by Covishield.

It is important to track the breakthrough infections for immune escape mutants, the report said.

August 4, 2021 0 comment

Uncategorized

MitraClip implant at Apollo Hospitals saves 41-year-old farmer who waited 91 days for a heart transplant!

by Medically Speaking Team August 4, 2021

written by Medically Speaking Team

Apollo Hospitals, Asia’s foremost and most trusted healthcare group, today announced a successful MitraClip implant on a 41-year-old male farmer who had waited for over three months in different hospitals for a heart transplant. The patient was back on his feet within a few days after the procedure, and might not even need a heart transplant.

Ms. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Group said, “As one of the few hospitals in India accredited to perform the MitraClip procedure, being able to save the life of a patient waiting for a heart transplant gives us the ability to offer hope to many others. Patients with severe/end-stage heart failure comprise up to 10% of patients suffering from heart disease. Research has shown that using MitraClip as a bridge to heart transplantation is safe and may even lead to functional improvements that permit patients to be removed from the transplant list. We are proud to have demonstrated this at Apollo Hospitals through the case of a 41 year old male patient who was waiting for a heart transplant for over three months. The success of this case has renewed our commitment to taking this cutting edge and revolutionary medical innovation to the people who need it the most. Also a vast majority of these cases were performed during the worst months of the second wave and this was possible only because of the stringent infection control protocol and the iron curtain that separates COVID and non-COVID patients in the hospital.”

Data from 119 patients in the International MitraBridge Registry on critically ill patients on a transplant list showed procedural success was achieved in 87.5% of cases, and 30-day survival was 100%.

Dr Preeta Reddy, Vice Chairperson Apollo Hospitals Group, with Dr Sai Satish, Sr Interventional Cardiologist along with a 41 year old farmer who got MitraClip procedure done.

Dr. Sai Satish, Senior Interventional Cardiologist, Apollo Hospitals said, “The MitraClip is a small metal clip with a polyester fabric that is inserted in place to fix the leaky mitral valve thereby ensuring that the blood flow is in the right direction. It is a globally accepted procedure for patients with heart failure. Patients with moderate to severe or severe primary and secondary mitral regurgitation who are not improving on medical treatment can opt for this minimally invasive solution that offers them a vastly improved quality of life and health.”

“For three years now we have been performing this procedure on patients we think are suitable candidates and we have seen incredible results in the quality of life they are able to return to, post procedure. Our experience in this domain has enabled us to achieve many milestones including back-to-back MitraClip implants in four very sick patients in just one day earlier this year, at the height of the second wave of the pandemic. Today, we are at pole position; 70% of all MitraClips in India to date have been performed at Apollo Hospitals and we are only looking at bigger and more remarkable milestones in the journey ahead,” added Dr. Sai Satish.

MitraClip was introduced in India just three years ago. The first MitraClip was implanted in 2003 in a patient in the US. It was a game-changing procedure and was made commercially available in Europe in 2008 and in the US in 2013. Today over 100,000 patients in more than 50 countries have undergone the MitraClip procedure.

MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery. The minimally invasive MitraClip procedure is effective in both functional and degenerative mitral regurgitation. The procedure is performed percutaneously in a cath lab and the device is removable and repositionable. These important attributes contribute to the safety of this procedure. Diligent patient selection is an important element to ensure success.

Repeat hospitalisations are avoided after the MitraClip procedure as compared to conventional surgery, making it economical in the long run and patients are able to recover and resume life in a very short span of time.”

India’s first two scientific papers on MitraClip have both been published from Apollo Hopsitals, one on the first case and the second paper on the first seven cases with a year’s follow-up showing excellent outcomes. Dr. Sai Satish of Apollo Hospitals is the only Indian author involved in the authorship of the APAC guidelines for MitraClip implants. Asia’s first MitraClip training programme that included theory and four cases over two days was also conducted at Apollo Hospitals, cementing its position as a Centre of Excellence in Interventional Cardiology.

August 4, 2021 0 comment

Uncategorized

Job Alert: 18 vacancies for the post of Gynaecologist, Anesthetist, Pediatrician and Pathologist, Details below

by Medically Speaking Team August 4, 2021

written by Medically Speaking Team

Chief Medical Health Officer (CMHO) announced the latest recruitment notification for the post of Gynecologist, Pediatrician, Anaesthetist, and Pathologist. CMHO has about 18 vacant positions to fulfill in Mahasamund. Applications are invited from eligible candidates having MBBS, MS / MD qualifications. Interested candidates can refer to this page for more new latest job notifications from all over india. However, Aspirants with essential qualifications can appear for CMHO Walk-in-Interview Recruitment 2021 on the scheduled date.

Vacancy Details and Eligibility criteria – CMHO Notification 2021:

Name of the Post	No.of Vacancies	Educational Qualification
Gynecologist	04	MBBS + MS / MD / DNB
Pediatrician	04	MBBS / MD
Anesthetist	05
Pathologist	05
Total	18

Age Limit:

Applicants age should be

Minimum age of 18 years
Maximum age of 70 years as on closing date of application.

Pay Scale:

Consolidated remuneration will be paid up to Rs. 10300 per month.

Selection Process:

Candidates will be selected based on performance in the Interview.

Walk-in Procedure of CMHO Recruitment 2021:

Desired candidates who are eligible may attend for CMHO Walk-in-Interview Recruitment 2021 with the following documents.

Application Form (Download below).
Educational Qualification, Experience certificates.
Age Proof, Caste Certificates, and other testimonials.
Recent passport size photographs.
Original documents for verification at the time of interview.

Walk-in-Interview Date & Reporting Time: 16th August 2021 at 10:30 AM.

Venue: Office of Chief Medical Health Officer, Mahasamund, Raipur, Chhattisgarh.

August 4, 2021 0 comment

Uncategorized

ICPA Introduces Denture Management Kit For The Elderly

by Medically Speaking Team August 4, 2021

written by Medically Speaking Team

ICPA Health Products Ltd (ICPA), India’s leading pharmaceutical company and pioneers in the oral-health segment has introduced its latest offering, a denture management kit – Replay Kit, for the elderly. The kit consists of a complete denture hygiene and maintenance routine including a denture storage container, Fixon adhesive cream, Clinsodent cleanser and Clinsodent brush. Realizing the unique problems encountered by denture users, the company ICPA has assembled the kit for easy-to-use, everyday denture management.

The denture adhesive called Fixon Cream helps hold the dentures securely in the mouth helping the user eat, speak, look and feel better. It seals out any food particles and prevents its ingress underneath the denture surface and increases the bite force by as much as 10 times.

The denture cleanser called Clinsodent consists of effervescent cleansing tablets that help clean all water insoluble residues from dentures. Its antibacterial formula kills germs which cause odour and plaque.

The Clinsodent brush is designed for optimum hygiene. The two types of nylon bristles on opposite heads of the brush are designed to effectively clean all surfaces and grooves in the dentures. The contoured design maximises control while handling the brush.

August 4, 2021 0 comment